The winds of fortune are blowing in Gamida Cell’s favor as the average one-year price target for Gamida Cell (NasdaqGM:GMDA) crescendos to 4.42 per share, marked by an 8.33% rise from the earlier projection of 4.08 on January 16, 2024.
This revamped price objective is an amalgamation of multiple estimates put forth by analysts. Spanning from a low of 2.02 to a high of 6.30 per share, the newfound average represents a staggering 1,207.30% upsurge from the latest recorded closing price of 0.34 per share.
Fund Sentiment: A Closer Look
Delving into the depths of ownership tides, a recent study reveals that 77 funds or institutions have vested interests in Gamida Cell – a slight dip of 6.10% (5 owners) observed in the last quarter alone.
The average portfolio weight allocated by all funds to GMDA now stands at 0.03%, signifying a notable plummet of 57.59%. Collectively, the total shares owned by institutions have dwindled by 6.65% over the past three months to rest at 36,564K shares.
The put/call ratio of GMDA, standing at 0.14, paints an optimistic picture of future prospects, alluding to a predominantly bullish outlook.
Insight into Shareholder Actions
Among the notable shareholders, Levin Capital Strategies emerges with 6,024K shares equating to 4.54% ownership of the company. Their recent filing reveals a 55.29% surge compared to the previous quarter, although the institution pruned its portfolio allocation towards GMDA by 18.82%.
On the other hand, Meitav Dash Investments holds 3,655K shares, translating to a 2.76% stake in Gamida Cell, with no change recorded in the last quarter.
Meanwhile, Millennium Management showcases a stake of 2,569K shares, representing 1.94% ownership. Surprisingly, their latest filing signifies a monumental 100.00% hike from a prior report of 0K shares.
Furthermore, QVG2Q – Growth Portfolio Investor Class holds 2,212K shares, reflecting a 1.67% ownership stake with no variations observed in the recent quarter.
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet retains 2,212K shares, mirroring a 1.67% ownership share with no adjustments reported during the last quarter.
Embarking on the Gamida Cell Journey
Gamida Cell is a pioneer in advanced cell therapy, striving to unlock cures for patients grappling with blood cancers and grave blood disorders. Leveraging its cutting-edge cell expansion platform, the company endeavors to fashion therapies with the potential to redefine the benchmarks of care in critical areas of medical urgency.
Description provided by Gamida Cell itself.
Fintel stands tall as one of the most expansive investing research platforms, catering to individual investors, traders, financial advisors, and compact hedge funds. Our data enshrouds the global sphere, encompassing fundamentals, analyst insights, ownership statistics, fund sentiments, options data, insider trading intel, options flow, unconventional options trades, and much more.
Click to Learn More
Originally reported on Fintel.
The expressions and viewpoints articulated in this narrative are those of the author alone and may not necessarily mirror the stance of Nasdaq, Inc.
